Mary Reumuth Kala Pharmaceuticals, Inc. (KALA) insider trading activity

Mary Reumuth is CHIEF FINANCIAL OFFICER of Kala Pharmaceuticals, Inc.. Currently has a direct ownership of 28,906 shares of KALA, which is worth approximately $20,523. The most recent transaction as insider was on Oct 23, 2025, when has been sold 967 shares (Common Stock) at a price of $0.82 per share, resulting in proceeds of $792. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.9K

53.45% 3M change

51.97% 12M change

Total Value Held $20,523

Mary Reumuth Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 23 2025	SELL Open market or private sale	$792 $0.82 p/Share	967 Reduced 3.24%	28,906 Common Stock
Oct 22 2025	SELL Open market or private sale	$26,750 $0.83 p/Share	32,230 Reduced 51.9%	29,873 Common Stock
Jun 24 2025	SELL Open market or private sale	$14,560 $4.01 p/Share	3,631 Reduced 5.52%	62,100 Common Stock
Jun 03 2025	SELL Open market or private sale	$10,659 $3.74 p/Share	2,850 Reduced 4.16%	65,731 Common Stock
Jan 06 2025	SELL Open market or private sale	$13,016 $7.63 p/Share	1,706 Reduced 2.43%	68,581 Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	10,100 Added 12.56%	70,287 Common Stock
Jun 26 2024	SELL Open market or private sale	$19,774 $4.75 p/Share	4,163 Reduced 6.47%	60,187 Common Stock

May 31 2024	SELL Open market or private sale	$10,876 $6.09 p/Share	1,786 Reduced 2.7%	64,350 Common Stock
Jan 04 2024	SELL Open market or private sale	$8,269 $6.74 p/Share	1,227 Reduced 1.82%	66,136 Common Stock
Jan 04 2024	BUY Grant, award, or other acquisition	-	4,600 Added 6.39%	67,363 Common Stock
Jun 22 2023	BUY Grant, award, or other acquisition	-	36,144 Added 36.54%	62,763 Common Stock
May 31 2023	BUY Grant, award, or other acquisition	-	14,736 Added 35.63%	26,619 Common Stock
Jan 04 2023	SELL Open market or private sale	$1,712 $28.54 p/Share	60 Reduced 0.5%	11,883 Common Stock
Jan 04 2023	BUY Grant, award, or other acquisition	-	9,525 Added 44.37%	11,943 Common Stock
Oct 26 2022	SELL Open market or private sale	$1,263 $6.51 p/Share	194 Reduced 7.43%	2,418 Common Stock
Jun 27 2022	SELL Open market or private sale	$967 $0.37 p/Share	2,613 Reduced 1.96%	130,595 Common Stock
Jan 04 2022	SELL Open market or private sale	$3,705 $1.3 p/Share	2,850 Reduced 2.09%	133,208 Common Stock
Oct 26 2021	SELL Open market or private sale	$17,008 $1.8 p/Share	9,449 Reduced 6.49%	136,058 Common Stock
Jun 28 2021	SELL Open market or private sale	$14,148 $5.77 p/Share	2,452 Reduced 1.66%	145,507 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	22,666 Added 13.28%	147,959 Common Stock
Oct 26 2020	BUY Grant, award, or other acquisition	-	61,000 Added 32.74%	125,293 Common Stock

Mary Reumuth

CHIEF FINANCIAL OFFICER

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KALA shares.

Notify only if

Value

Insider Trading

Get notified when an Kala Pharmaceuticals, Inc. insider buys or sells KALA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kala Pharmaceuticals, Inc.

Track Activities on KALA

Account